“…Plasmablasts, mDCs and pDCs levels as well as CD3/NK ratio, are associated to a worse respiratory status, while Tn/Te ratio could detect non-severe patients who will require high-flow oxygen devices during follow up. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Numerous patient-level, disease-specific, and therapy-related factors may impact outcomes of COVID-19 among patients with HM, and we are currently analyzing additional data to better understand the factors which make this disease group more susceptible to severe infection. [Figure: see text] DISCLOSURES: Kuzel:  Sanofi-Genzyme Genomic Health Tempus laboratories Bristol Meyers Squibb: Honoraria; Genomic Health: Membership on an entity's Board of Directors or advisory committees; Exelixis: Membership on an entity's Board of Directors or advisory committees; Cardinal Health: Membership on an entity's Board of Directors or advisory committees; Abbvie: Other; Curio Science: Membership on an entity's Board of Directors or advisory committees; AmerisourceBergen Corp: Membership on an entity's Board of Directors or advisory committees; CVS: Membership on an entity's Board of Directors or advisory committees; Tempus Laboratories: Membership on an entity's Board of Directors or advisory committees; Bristol Meyers Squibb: Membership on an entity's Board of Directors or advisory committees; Merck: Other: Data Monitoring Committee Membership; Amgen: Other: Data Monitoring Committee Membership; SeaGen: Other: Data Monitoring Committee Membership; Medpace: Other: Data Monitoring Committee Membership.…”
Enlace del recurso
Enlace del recurso

“…The duration of a humoral response against COVID-19, protective antibody titer and connection with clinical outcomes in CML pts need further evaluation in parallel with a common population. [Figure: see text] DISCLOSURES: Chelysheva:  Pfizer: Speakers Bureau; Pharmstandart: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau; Novartis Pharma: Speakers Bureau. …”
Enlace del recurso
Enlace del recurso

“…However, our results indicate MesenCure's potential in relieving local inflammation while giving the patient a fighting chance against viremia. [Figure: see text] DISCLOSURES: Bronshtein:  Bonus BioGroup: Current Employment. …”
Enlace del recurso
Enlace del recurso

“…Many questions remain including the protective benefit of immune response, the duration of response, and the potential value of booster vaccinations in non-responders. [Figure: see text] DISCLOSURES: Rowley:  ReAlta Life Sciences: Consultancy.…”
Enlace del recurso
Enlace del recurso

“…These data suggest a need for oral Tx that can prolong remission while reducing clinic and inpatient visits, and that can bridge the gap until HSCT. [Figure: see text] DISCLOSURES: Chen:  Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. …”
Enlace del recurso
Enlace del recurso

“…A subsequent qualitative study exploring COVID vaccine hesitancy amongst persons with SCD in BC is being explored. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…In the presence of an inhibitory anti-TFPI antibody, peak plasma thrombin generation was enhanced in COVID-19 in contrast to that observed among SARS-CoV-2 PCR negative hospitalised patients (339.6+25.2 vs 247.4+10.1, p=0.01). [Figure: see text] DISCLOSURES: Maguire:  Actelion: Research Funding; Bayer Pharma: Research Funding. …”
Enlace del recurso
Enlace del recurso

“…The possibility for these patients to have mounted a cellular response should also be considered, which was not investigated here. [Figure: see text] DISCLOSURES: Moreau:  Celgene BMS: Honoraria; Sanofi: Honoraria; Abbvie: Honoraria; Oncopeptides: Honoraria; Amgen: Honoraria; Janssen: Honoraria.…”
Enlace del recurso
Enlace del recurso

“…It remains to see if vaccines can play a key role to protect this special group of pts. [Figure: see text] DISCLOSURES: Anagnostopoulos:  Abbvie: Other: clinical trials; Sanofi: Other: clinical trials ; Ocopeptides: Other: clinical trials ; GSK: Other: clinical trials; Incyte: Other: clinical trials ; Takeda: Other: clinical trials ; Amgen: Other: clinical trials ; Janssen: Other: clinical trials; novartis: Other: clinical trials; Celgene: Other: clinical trials; Roche: Other: clinical trials; Astellas: Other: clinical trials .…”
Enlace del recurso
Enlace del recurso

“…D-dimer ≥ 2500 and elevated PT were associated with higher rate of thrombosis and death. [Figure: see text] DISCLOSURES: Abdulhaq:  BMS, Alexion, Oncopeptides, Morphosys, Pfizer, Norvartis: Honoraria; Oncopeptides, Alexion, Amgen: Speakers Bureau; Morphosys, BMS, Amgen: Membership on an entity's Board of Directors or advisory committees.…”
Enlace del recurso
Enlace del recurso

“…These patients should be recognised and instructed to take appropriate precautions. [Figure: see text] DISCLOSURES: Yeshurun:  Astellas: Consultancy; Jannsen: Consultancy. …”
Enlace del recurso
Enlace del recurso

“…For the other patients, who represent the frailer subgroup, in the absence of a documented immune response after 2 doses of vaccine, the option of a third dose in order to increase the probability of response should be evaluated in prospective clinical trials. [Figure: see text] DISCLOSURES: Viardot:  Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; F. …”
Enlace del recurso
Enlace del recurso

“…However, the present study did not examine potential confounding effects between these factors and these findings should be elaborated further in larger patient cohorts. [Figure: see text] DISCLOSURES: Aurer:  Novartis: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Swixx/BMS: Honoraria; sanofi genzyme: Consultancy, Honoraria; Teva/Pilva: Honoraria; Abbvie: Consultancy, Honoraria; Eusapharma: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; takeda: Consultancy, Honoraria. …”
Enlace del recurso
Enlace del recurso

“…We are currently evaluating if a COVID-19 diagnosis has any effect on long term transplant related complications and outcomes in this population. [Figure: see text] DISCLOSURES: Chaudhary:  Angeles Therapeutics: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Other: Founder, Patents & Royalties: Cell therapy ; Celldex: Current equity holder in publicly-traded company; Moderna: Current equity holder in publicly-traded company; Pancella: Consultancy; Oncotartis: Consultancy; Athelas: Consultancy, Current holder of stock options in a privately-held company; TCR2: Current equity holder in publicly-traded company; Allogene: Current equity holder in publicly-traded company. …”
Enlace del recurso
Enlace del recurso

“…Watchful clinical and laboratory monitoring is advised, in order to promptly recognize severe hemolytic flares in both treated and naïve patients. [Figure: see text] DISCLOSURES: Fattizzo:  Novartis: Speakers Bureau; Kira: Speakers Bureau; Alexion: Speakers Bureau; Annexon: Consultancy; Momenta: Honoraria, Speakers Bureau; Apellis: Speakers Bureau; Amgen: Honoraria, Speakers Bureau. …”
Enlace del recurso
Enlace del recurso

“…In particular, we show that vaccine disinformation received from friends and social media is a significant reason for vaccine refusal. [Figure: see text] DISCLOSURES: Calip:  Pfizer: Research Funding; Roche: Current equity holder in publicly-traded company; Flatiron Health: Current Employment. …”
Enlace del recurso
Enlace del recurso

“…In the prospective cohort of our study, pathophysiology of the viral disease did not seem related to cytokine storm-mediated inflammation. [Figure: see text] DISCLOSURES: Protheroe:  Jazz Pharmaceuticals: Honoraria; Astellas: Honoraria; Kite Gilead: Honoraria. …”
Enlace del recurso
Enlace del recurso

“…The serological response to SARS-CoV-2 vaccination observed in pts. with early disease with no need of therapy may help to identify CLL pts who are expected to achieve an optimal response to COVID-19 vaccine similarly to age- and sex-matched controls. [Figure: see text] DISCLOSURES: Molica:  Astrazeneca: Honoraria; Abbvie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria.…”
Enlace del recurso
Enlace del recurso

“…Translation of H84T-BanLec CAR-NK cells to the clinic may have promise as an effective cellular therapy for SARS-CoV-2 infection. [Figure: see text] DISCLOSURES: Markovitz:  University of Michigan: Patents & Royalties: H84T BanLec and of the H84T-driven CAR construct. …”
Enlace del recurso
Enlace del recurso